Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenomatous Polyposis Coli
Phase III Trials of FGN-1 Begin for Precancerous Colon Polyp Therapy
May 26th, 1997
Cell Pathways Inc., West Conshohocken, Pennsylvania, announced the start of a multi-national Phase III trial of its lead investigational drug, FGN-1, as preventative therapy for precancerous colon polyps in patients with adenomatous polyposis coli, (APC; also known as familial adenomatous polyposis, FAP). Colon polyps are often precursors to colorectal cancers. Patients with APC, a relatively rare inherited disease, form large numbers of colon polyps and face a high risk of colon cancer at an early age. Colon polyps also occur sporadically, but repeatedly, in a large portion of the general U.S. population. As these lesions are known to precede the...
Source: Cancer Weekly (1997-05-26)
|
